Ignite Creation Date:
2024-05-05 @ 11:31 AM
Last Modification Date:
2024-10-26 @ 9:09 AM
Study NCT ID:
NCT00067236
Status:
COMPLETED
Last Update Posted:
2011-11-04
First Post:
2003-08-13
Brief Title:
Study of Oral PG-116800 Following a Heart Attack
Sponsor:
Procter and Gamble
Organization:
Procter and Gamble
Study Overview
Official Title:
A Multicenter Randomized Double-blind Placebo-controlled Study of Oral PG-116800 Following a Heart Attack
Status:
COMPLETED
Status Verified Date:
2011-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The main purpose of the study is to test whether a possible new drug called PG-116800 can prevent some of the damage to heart muscle in patients who have had a heart attack The study will also supply information regarding possible uses of this compound in cardiovascular disease
Detailed Description:
Heart attacks cause damage to heart muscle that can weaken the heart and lead to changes in the shape and pumping ability of the heart These changes can lead to heart failure An enzyme called metalloproteinase MMP plays a role in this damage
The main purpose of the study is to test whether a possible new drug called PG-116800 that interferes with the MMP enzyme can prevent some of the damage to heart muscle in patients who have had a heart attack The study will also supply information regarding possible uses of this compound in cardiovascular disease
This is a Phase II proof-of-concept study that is it is a first attempt to treat sick people with the drug to see if it works
The study is interventional since we will be using a drug to interfere with the heart tissue damage that follows a heart attack
The main purpose of the study is to test whether a possible new drug called PG-116800 that interferes with the MMP enzyme can prevent some of the damage to heart muscle in patients who have had a heart attack The study will also supply information regarding possible uses of this compound in cardiovascular disease
This is a Phase II proof-of-concept study that is it is a first attempt to treat sick people with the drug to see if it works
The study is interventional since we will be using a drug to interfere with the heart tissue damage that follows a heart attack
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None